

<b>Technology appraisal (TA)</b> Titles are hyperlinks to full guidance	<b>Date of TA Release</b> (N.B. if exact date is not specified in NICE documentation, the last day of the month published will be employed)	<b>Adherence of local formulary to NICE</b>				
		<b>Yes</b> <i>(mark 'x' if applicable)</i>	<b>N/A</b> <i>(mark 'x' if applicable)</i>	<b>Date of local decision</b> (DD/MM/YY)	<b>Time to implement</b> (days)	<b>Notes</b> (e.g. Additional stipulations, rationale, method of making available)
<a href="#">Dinutuximab beta for treating neuroblastoma [TA538]</a>	22/08/2018		X	22/08/2018	0	
<a href="#">Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA537]</a>	08/08/2018	X		16/08/2018	8	
<a href="#">Alectinib for untreated ALK-positive advanced non-small-cell lung cancer [TA536]</a>	08/08/2018	X		04/09/2018	27	
<a href="#">Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [TA535]</a>	08/08/2018	X		04/09/2018	27	
<a href="#">Dupilumab for treating moderate to severe atopic dermatitis [TA534]</a>	01/08/2018	X		16/08/2018	15	
<a href="#">Ocrelizumab for treating relapsing–remitting multiple sclerosis [TA533]</a>	25/07/2018	X		04/09/2018	41	
<a href="#">Cenegermin for treating neurotrophic keratitis [TA532]</a>	18/07/2018	X		18/07/2018	0	
<a href="#">Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA531]</a>	18/07/2018	X		04/09/2018	48	
<a href="#">Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy [TA530]</a>	04/07/2018	X		17/07/2018	13	
<a href="#">Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [TA529]</a>	04/07/2018	X		17/07/2018	13	
<a href="#">Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA528]</a>	04/07/2018	X		17/07/2018	13	
<a href="#">Beta interferons and glatiramer acetate for treating multiple sclerosis [TA527]</a>	27/06/2018	X		17/07/2018	20	
<a href="#">Arsenic trioxide for treating acute promyelocytic leukaemia [TA526]</a>	13/06/2018	X		17/07/2018	34	
<a href="#">Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA525]</a>	13/06/2018	X		17/07/2018	34	
<a href="#">Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma [TA524]</a>	13/06/2018	X		17/07/2018	34	
<a href="#">Midostaurin for untreated acute myeloid leukaemia [TA523]</a>	13/06/2018	X		17/07/2018	34	
<a href="#">Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA522]</a>	13/06/2018	X		17/07/2018	34	
<a href="#">Guselkumab for treating moderate to severe plaque psoriasis [TA521]</a>	13/06/2018	X		21/06/2018	8	

<a href="#">Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy [TA520]</a>	16/05/2018	X		17/07/2018	62	
<a href="#">Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA519]</a>	25/04/2018	X		17/07/2018	83	
<a href="#">Tocilizumab for treating giant cell arteritis [TA518]</a>	18/04/2018	X		17/07/2018	90	
<a href="#">Avelumab for treating metastatic Merkel cell carcinoma [TA517]</a>	11/04/2018	X		17/07/2018	97	
		% "Yes"	% "N/A"	-	<b>Average implement time (days)</b>	
<b>Adherence statistics for 2018-19</b>		<b>95.0%</b>	<b>5.0%</b>		<b>33</b>	

